Hypertension and Cardiovascular Mortality in Patients with Cushing Syndrome

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Metabolic Disorders

Background:

• Cushing syndrome is linked to elevated mortality rates.
• Cardiovascular complications are the primary cause of death in these patients.
• Hypertension, diabetes, obesity, and dyslipidemia are key drivers of cardiovascular risk.

Purpose of the Study:

• To highlight the importance of evaluating and treating comorbidities in Cushing syndrome.
• To guide the specific management of cardiovascular risk factors in hypercortisolism.
• To emphasize the impact of cortisol control on comorbidity management.

Main Methods:

• Review of clinical guidelines and evidence for managing comorbidities in Cushing syndrome.
• Analysis of the pathophysiological links between hypercortisolism and cardiovascular diseases.
• Discussion of pharmacotherapeutic strategies for hypertension, diabetes, and dyslipidemia.

Main Results:

• Cardiovascular risk factors require thorough assessment before and after hypercortisolism treatment.
• Specific treatments targeting hypertension, diabetes, obesity, and dyslipidemia are essential.
• Renin-angiotensin system inhibitors and mineralocorticoid antagonists are recommended antihypertensives.
• Normalization of cortisol levels is critical for effective comorbidity management.

Conclusions:

• Aggressive management of hypertension, diabetes, obesity, and dyslipidemia is vital for reducing cardiovascular mortality in Cushing syndrome.
• Tailored treatment strategies, including specific antihypertensives, are necessary.
• Achieving cortisol normalization significantly improves the manageability of associated comorbidities.